Abano Healthcare Group Limited is pleased to present its FY17 Annual Review. This accompanies the Financial Statements which were released on 26 July 2017.
To view the full 2017 Annual Review and Report please click here: www.abano.co.nz/investors/shareholder-reports/2017-annual-report.
FY17 was another year of growth for our company as we continued to focus on building our businesses in the transTasman dental market, as well as increasing returns for our radiology investment.
Our vision is to build market leading brands and healthcare businesses that have the competitive advantage of size, scale and reputation. We see the $11-billion revenue trans-Tasman dental market as our primary opportunity, and our goal is to create a $1-billion revenue dental business.
Our largest opportunity is in the Australian dental market, which is approximately 12 times larger than the New Zealand market and we are looking to step up our dental growth plans, particularly in Australia.
With the increase in underlying NPAT per share, the Board was pleased to declare a final FY17 dividend of 20 cents per share. This takes Abano’s full year dividends to 36 cents per share, a 20% increase on last year and equal to 67% of Underlying NPAT.
We have a track record of delivering on our promises and we remain focused on ensuring we meet and exceed the expectations of our shareholders. We are well positioned for the continued growth of our company and are committed to balancing our growth requirements with attractive dividend payments.